A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method

Computers in Biology and Medicine

Volumn 41, Issue 11, 2011, Pages 1006-1013

  Zhong, Lei ^a,b   Ma, Chang Ying ^a   Zhang, Hui ^a   Yang, Li Jun ^a   Wan, Hua Lin ^a   Xie, Qing Qing ^a   Li, Lin Li ^b   Yang, Sheng Yong ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Breast cancer resistance protein (BCRP); Classification model; Non substrate; Substrate; Support vector machine

Indexed keywords

ANTICANCER DRUG; BREAST CANCER RESISTANCE PROTEINS; CLASSIFICATION MODEL; CLINICAL USE; DRUG DISCOVERY; MACHINE LEARNING METHODS; MULTIDRUG RESISTANCE; NON-SUBSTRATE; PREDICTION ACCURACY; PREDICTION MODEL; SCREENING TOOL; SUPPORT VECTOR; THERAPEUTIC EFFECTS; TRAINING SETS;

DISEASES; FORECASTING; GALLIUM ALLOYS; MATHEMATICAL MODELS; PROTEINS; SUPPORT VECTOR MACHINES;

SUBSTRATES;

ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; DAUNORUBICIN; DIPYRIDAMOLE; ENROFLOXACIN; EPIRUBICIN; ESTRADIOL; ETOPOSIDE; FEXOFENADINE; GLIBENCLAMIDE; GREPAFLOXACIN; IMATINIB; IRINOTECAN; LAMIVUDINE; LURTOTECAN; MENADIONE; MITOXANTRONE; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL] 2 BUTYNAMIDE; NITROFURANTOIN; NOVOBIOCIN; OFLOXACIN; OXFENDAZOLE; PROBENECID; PROGESTERONE; PUROMYCIN; QUERCETIN; RIBOFLAVIN; SALAZOSULFAPYRIDINE; TOPOTECAN; UNINDEXED DRUG;

ARTICLE; BREAST CANCER; COMPUTER PROGRAM; DECISION TREE; GENETIC ALGORITHM; MODEL; PREDICTION; PRIORITY JOURNAL; SUPPORT VECTOR MACHINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; SUPPORT VECTOR MACHINES;

EID: 82655172381     PISSN: 00104825     EISSN: 18790534     Source Type: Journal    
DOI: 10.1016/j.compbiomed.2011.08.009     Document Type: Article

References (60)

1. Saito H., Hirano H., Ishikawa T. High-speed screening and quantitative SAR analysis of human ABC transporter abcg2 for molecular modeling of anticancer drugs to circumvent multidrug resistance. Mini-Rev. Med. Chem. 2007, 7:1009-1018.
2. Mao Q.C., Unadkat J.D. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005, 7:E118-E133.
3. Hazai E., Bikádi Z. Homology modeling of breast cancer resistance protein (ABCG2). J. Struct. Biol. 2008, 162:63-74.
4. Saito H., Hirano H., Nakagawa H., Fukami T., Oosumi K., Murakami K., Kimura H., Kouchi T., Konomi M., Tao E., Tsujikawa N., Tarui S., Nagakura M., Osumi M., Ishikawa T., New A. Strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. J. Pharm. Exp. Ther. 2006, 317:1114-1124.
5. Han Y., Riwanto M., Go M.L., Rachel Ee P.L. Modulation of breast cancer resistance protein (BCRP/ABCG2) by non-basic chalcone analogues. Eur. J. Pharm. Sci. 2008, 35:30-41.
6. Özvegy C., Váradi A., Sarkadi B. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. J. Biochem. 2002, 277:47980-47990.
7. Szakács G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discovery 2006, 5:219-234.
8. Sai Y., Tsuji A. Transporter-mediated drug delivery: recent progress and experimental approaches. Drug Discovery Today 2004, 9:712-720.
9. Kusuhara H., Sugiyama Y. ATP-binding cassette, subfamily G (ABCG family). Pflugers Arch. Eur. J. Physiol. 2007, 453:735-744.
10. Breedveld P., Zelcer N., Pluim D., Sönmezer Ö., Tibben M.M., Beijnen J.H., Schinkel A.H., van Tellingen O., Borst P., Schellens J.H.M. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004, 64:5804-5811.
11. Hirano M., Maeda K., Matsushima S., Nozaki Y., Kusuhara H., Sugiyama Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol. Pharmacol. 2005, 68:800-807.
12. Maliepaard M., van Gastelen M.A., Tohgo A., Hausheer F.H., van Waardenburg R.C.A.M., de Jong L.A., Pluim D., Beijnen J.H., Schellens J.H.M. Circumvention of breast cancer resistance protein (BCRP)-mediated Resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin. Cancer Res. 2001, 7:935-941.
13. Muenster U., Grieshop B., Ickenroth K., Gnoth M.J. Characterization of substrates and inhibitors for the in vitro assessment of BCRP mediated drug-drug interactions. Pharm. Res. 2008, 25:2320-2326.
14. Li H., Yap C.W., Xue Y., Li Z.R., Ung C.Y., Han L.Y., Chen Y.Z. Statistical learning approach for predicting specific pharmacodynamic, pharmacokinetic, or toxicological properties of pharmaceutical agents. Drug Dev. Res. 2006, 66:245-259.
15. van de Waterbeemd H., Gifford E. ADMET in silico modelling: towards prediction paradise?. Nat. Rev. Drug Discovery 2003, 2:192-204.
16. Chen S.W., Li Z.R., Li X.Y. Prediction of antifungal activity by support vector machine approach. J. Mol. Struct. Theochem. 2005, 731:73-81.
17. Xue Y., Yap C.W., Sun L.Z., Cao Z.W., Wang J.F., Chen Y.Z. Prediction of P-glycoprotein substrates by a support vector machine approach. J. Chem. Inf. Comput. Sci. 2004, 44:1497-1505.
18. Huang C.L., Wang C.J. A GA-based feature selection and parameter optimization for support vector machines. Expert Syst. Appl. 2006, 31:231-240.
19. H. Fröhlich, O. Chapelle, in: Proceedings of the Fifteenth IEEE International Conference on Tools with Artificial Intelligence, Sacramento, CA, USA, 2003.
20. Fröhlich H., Wegener J., Zell A. Towards optimal descriptor subset selection with support vector machines in classification and regression. QSAR Combinatorial Sci. 2004, 23:311-318.
21. Zhang H., Chen Q.Y., Xiang M.L., Ma C.Y., Huang Q., Yang S.Y. In silico prediction of mitochondrial toxicity by using GA-CG-SVM approach. Toxicol. In Vitro 2009, 23:134-140.
22. Zhang H., Xiang M.L., Huang Q., Li W., Xie Y., Wei Y.Q., Yang S.Y. Three-class classification models of logS and logP derived by using GA-CG-SVM approach. Mol. Diversity 2009, 13:261-268.
23. Yang S.Y., Huang Q., Li L.L., Ma C.Y., Zhang H., Bai R., Teng Q.Z., Xiang M.L., Wei Y.Q. An integrated scheme for feature selection and parameter setting in the support vector machine modeling and its application to the prediction of pharmacokinetic properties of drugs. Artif. Intell. Med. 2009, 46:155-163.
24. Lucasius C.B., Kateman G. Understanding and using genetic algorithms. Part 1. Concepts, properties and context. Chemometrics Intell. Lab. Syst. 1993, 19:1-33.
25. S. Keerthi, V. Sindhwani, O. Chapelle, An efficient method for gradient-based adaptation of hyperparameters in SVM models, in: B. Schölkopf, J. Platt, T. Hofmann (Eds.), Advances in Neural Information Processing Systems~20 (NIPS~2006), Vancouver, Canada, (2007).
26. Ma C.Y., Yang S.Y., Zhang H., Xiang M.L., Huang Q., Wei Y.Q. Prediction models of human plasma protein binding rate and oral bioavailability derived by using GA-CG-SVM method. J. Pharm. Biomed. Anal. 2008, 47:677-682.
27. Zhang H., Li W., Xie Y., Wang W.J., Li L.L., Yang S.Y. Rapid and accurate assessment of seizure liability of drugs by using an optimal support vector machine method. Toxicol. in Vitro 2011, 10.1016/j.tiv.2011.05.015.
28. Li H., Ung C.Y., Yap C.W., Xue Y., Li Z.R., Cao Z.W., Chen Y.Z. Prediction of genotoxicity of chemical compounds by statistical learning methods. Chem. Res. Toxicol. 2005, 18:1071-1080.
29. Votano J.R., Parham M., Hall L.M., Hall L.H., Kier L.B., Oloff S., Tropsha A. QSAR modeling of human serum protein binding with several modeling techniques utilizing structure-information representation. J. Med. Chem. 2006, 49:7169-7181.
30. Vapnik V. Statistical Learning Theory 1998, Wiley, New York.
31. Burges C.J.C. A tutorial on support vector machines for pattern recognition. Data Min. Knowl. Discovery 1998, 2:127-167.
32. Wang Y., Chen X., Jiang W., Li L., Li W., Yang L., Liao M., Lian B., Lv Y., Wang S., Wang S., Li X. Predicting human MicroRNA precursors based on an optimized feature subset generated by GA-SVM. Genomics 2011, 98:73-78.
33. Theilhaber J., Connolly T., Roman-Roman S., Bushnell S., Jackson A., Call K., Garcia T., Baron R. Finding genes in the C2C12 osteogenic pathway by k-nearest-neighbor classification of expression data. Genome Res. 2002, 12:165-176.
34. Pavek P., Merino G., Wagenaar E., Bolscher E., Novotna M., Jonker J.W., Schinkel A.H. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J. Pharmacol. Exp. Ther. 2005, 312:144-152.
35. Bachmeier C.J., Trickler W.J., Miller D.W. Drug efflux transport properties of 20,70-Bis(2-carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM) and its fluorescent free acid, BCECF. J. Pharm. Sci. 2004, 93:932-942.
36. Aida-Hyugaji S., Nakagawa H., Nomura J., Sakurai M., Nagashima U., Ishikawa T. Theoretical studies for molecular modeling of new camptothecin analogues. Croat. Chem. Acta 2007, 80:277-281.
37. Zamek-Gliszczynski M.J., Hoffmaster K.A., Humphreys J.E., Tian X., Nezasa K., Brouwer K.L.R. Differential Involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in Biliary Excretion of 4-Methylumbelliferyl Glucuronide and Sulfate in the Rat. J. Pharmcol. Exp. Ther. 2006, 319:459-467.
38. Doyle L.A., Ross D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003, 22:7340-7358.
39. Ejendal K.F.K., Hrycyna C.A. Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A. Mol. Pharmacol. 2005, 67:902-911.
40. Lemos C., Jansen G., Peters G.J. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Br. J. Cancer 2008, 98:857-862.
41. Takagi K., Dexheimer T.S., Redon C., Sordet O., Agama K., Lavielle G., Pierré A., Bates S.E., Pommier Y. Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters. Mol. Cancer Ther. 2007, 6:3229-3238.
42. Liu W., Baer M.R., Bowman M., Pera P., Zheng X., Morgan J., Pandey R.A., Oseroff A.R. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin. Cancer Res. 2007, 13:2463-2470.
43. Zhang S.Z., Yang X.N., Coburn R.A., Morris M.E. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem. Pharmacol. 2005, 70:627-639.
44. Enokizono J., Kusuhara H., Sugiyama Y. Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect. Drug Metab. Dispos. 2007, 35:209-214.
45. Chen Z.S., Robey R.W., Belinsky M.G., Shchaveleva I., Ren X.Q., Sugimoto Y., Ross D.D., Bates S.E., Kruh G.D. Transport of methotrexate, methotrexate polyglutamates, and 17Β-estradiol 17-(Β-d-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003, 63:4048-4054.
46. Seamon J.A., Rugg C.A., Emanuel S., Calcagno A.M., Ambudkar S.V., Middleton S.A., Butler J., Borowski V., Greenberger L.M. Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor. Mol. Cancer Ther. 2006, 5:2459-2467.
47. Ejendal K.F.K., Diop N.K., Schweiger L.C., Hrycyna C.A. The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding. Protein Sci. 2006, 15:1597-1607.
48. Özvegy-Laczka C., Hegedus T., Várady G., Ujhelly O., Schuetz J.D., Váradi A., Kéri G., orfi L., Német K., Sarkadi B. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol. Pharmacol. 2004, 65:1485-1495.
49. Adachi Y., Suzuki H., Schinkel A.H., Sugiyama Y. Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen. Mol. Pharmacol. 2005, 67:923-928.
50. Gupta A., Unadkat J.D., Mao Q.C. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J. Pharm. Sci. 2007, 96:3226-3235.
51. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 2006, 112:457-473.
52. Suzuki M., Suzuki H., Sugimoto Y., Sugiyama Y. ABCG2 transports sulfated conjugates of steroids and xenobiotics. J. Biol. Chem. 2003, 278:22644-22649.
53. Janvilisri T., Venter H., Shahi S., Reuter G., Balakrishnan L., van Veen H.W. Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J. Biol. Chem. 2003, 278:20645-20651.
54. Chearwae W., Shukla S., Limtrakul P., Ambudkar S.V. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol. Cancer Ther. 2006, 5:1995-2006.
55. Fantin M., Quintieri L., Kúsz E., Kis E., Glavinas H., Floreani M., Padrini R., Duda E., Vizler C. Pentoxifylline and its major oxidative metabolites exhibit different pharmacological properties. Eur. J. Pharmacol. 2006, 535:301-309.
56. Discovery Studio, Version 1.7, Accelrys, Inc., San Diego, CA, 2006.
57. VCCLAB, 2005, Virtual Computational Chemistry Laboratory. Available at: http://www.vcclab.org.
58. Breiman L., Sepctor P. Submodel selection and evaluation in regression. The X-random case. Int. Stat. Rev. 1992, 60:291-391.
59. C.W. Hsu, C.C. Chang, C.J. Lin, A practical guide to support vector classification, 2003, Available at: http://www.csie.ntu.edu.tw/~cjlin/papers/guide/guide.pdf.
60. P. Cunningham, S. Jane Delany, k-Nearest Neighbour Classifiers, Technical Report UCD-CSI-2007-4, March 27, (2007).